2 completed. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 2 |
Follow Urgency Incontinence: new trials by email Literature Review of Urgency Incontinence trials Research Report on Urgency Incontinence
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder Solifenacin succinate, Mirabegron, Placebo to match solifenacin - Urinary Bladder Overactive, Overactive Bladder | Phase 3 | Completed | Astellas Pharma Europe B.V. | 1829 | 2014-03-17 | 2024-10-31 |
| This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder Solifenacin succinate, Mirabegron, Placebo to match solifenacin succinate - Urinary Bladder Overactive, Urinary Bladder Diseases\Urologic Diseases | Phase 3 | Completed | Astellas Pharma Europe B.V. | 3527 | 2013-11-05 | 2024-10-31 |
Nocturia (2) · Urinary Bladder, Overactive (2) · Urinary Incontinence (2)
Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Lower Urinary Tract Symptoms (2) · Male Urogenital Diseases (2) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Urinary Bladder Diseases (2) · Urination Disorders (2) · Urogenital Diseases (2) · Urologic Diseases (2) · Urological Manifestations (2)
Solifenacin Succinate (2) · mirabegron (2)
Astellas Pharma Europe B.V. (2)
Australia (2) · Belgium (2) · Bulgaria (2) · Canada (2) · Czechia (2) · Denmark (2) · Estonia (2) · Finland (2) · Germany (2) · Hungary (2) · Italy (2) · Latvia (2) · Lithuania (2) · Malaysia (2) · Mexico (2)